ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals

NCT00396240 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

1294

Enrollment

INDUSTRY

Sponsor class

Stopped study cancelled prior to FSI

Conditions

Primary Hypercholesterolaemia

Interventions

DRUG: Rosuvastatin
PROCEDURE: Initiatives to improve compliance

Sponsor

AstraZeneca